Legend Biotech Co. (NASDAQ:LEGN) Holdings Increased by Aigen Investment Management LP

Aigen Investment Management LP increased its stake in Legend Biotech Co. (NASDAQ:LEGN) by 19.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,363 shares of the company’s stock after acquiring an additional 1,206 shares during the period. Aigen Investment Management LP’s holdings in Legend Biotech were worth $240,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Exane Asset Management bought a new position in Legend Biotech during the 4th quarter valued at $2,284,000. Matthews International Capital Management LLC grew its holdings in Legend Biotech by 14.9% during the fourth quarter. Matthews International Capital Management LLC now owns 1,185,516 shares of the company’s stock worth $38,577,000 after acquiring an additional 153,665 shares during the period. Nordea Investment Management AB raised its position in Legend Biotech by 14.2% in the fourth quarter. Nordea Investment Management AB now owns 266,232 shares of the company’s stock worth $8,684,000 after acquiring an additional 33,024 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Legend Biotech in the 3rd quarter valued at about $12,837,000. Finally, Westfield Capital Management Co. LP boosted its position in shares of Legend Biotech by 5.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,038,505 shares of the company’s stock valued at $245,526,000 after purchasing an additional 266,296 shares in the last quarter. Institutional investors and hedge funds own 70.89% of the company’s stock.

Legend Biotech Stock Performance

Shares of Legend Biotech stock opened at $35.26 on Monday. The stock has a market cap of $6.44 billion, a PE ratio of -37.12 and a beta of 0.19. Legend Biotech Co. has a 12 month low of $30.17 and a 12 month high of $69.24. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. The business has a fifty day simple moving average of $35.36 and a 200-day simple moving average of $41.45.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a report on Tuesday, January 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $86.00 price target on shares of Legend Biotech in a report on Monday, December 9th. Piper Sandler reiterated an “overweight” rating and set a $78.00 price objective on shares of Legend Biotech in a research report on Monday, December 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $79.50.

Legend Biotech Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).